Key terms
About SLRX
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SLRX news
Mar 28
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Mar 27
10:47am ET
Biotech Alert: Searches spiking for these stocks today
Feb 23
6:13am ET
Salarius Pharmaceuticals Announces Executive Restructuring and Cost-Saving Measures
Feb 22
8:04am ET
Salarius announces additional cost saving measures, CEO transitions to part-time
Jan 03
8:39am ET
Salarius announces Phase 1/2 trial of seclidemstat resumes patient enrollment
No recent news articles are available for SLRX
No recent press releases are available for SLRX
SLRX Financials
Key terms
Ad Feedback
SLRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SLRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
